Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in
Elena Tamborini1, Francesca Miselli, Tiziana Negri
1Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Purpose:
We have previously shown the presence of an activated platelet-derived growth factor (PDGF) receptor (PDGFR) B and its ligand PDGFB in a limited number of patients with clinical and radiological responses to imatinib mesylate treatment. This article describes the results of comprehensive molecular/biochemical analyses of the three receptors targeted by the drug (PDGFRB, PDGFRA, and KIT) in a series of 31 chordoma patients.
Experimental Design:
The presence and activation status of PDGFRB, PDGFRA, and KIT receptors were investigated by means of immunoprecipitation and Western blot analyses complemented by immunohistochemistry, their expression level was analyzed by means of real-time PCR, and the occurrence of activating point mutations was investigated by means of cDNA sequencing. The PDGFB, PDGFA, and stem cell factor cognate ligands were investigated by reverse transcription-PCR, and gene status was assessed by fluorescence in situ hybridization.
Results:
The results show that PDGFRB was highly expressed and phosphorylated, whereas PDGFRA and KIT were less expressed but phosphorylated and thus activated. These findings, together with the absence of gain-of-function mutations and the presence of the cognate ligands, strongly support the hypothesis that the activation mechanism is the autocrine/paracrine loop. No role seems to be played by gene amplification.
Conclusions:
In the light of our findings, the clinical benefit observed in chordoma patients treated with imatinib seems to be attributable to the switching off of all three receptors.
Insights
Imatinib treatment for chordoma appears to work by inhibiting three key receptors: platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT. This molecular understanding aids in developing targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Previous studies indicated activated platelet-derived growth factor receptor (PDGFR) B and its ligand PDGFB in imatinib-responsive chordoma patients.
- Chordoma is a rare bone tumor with limited treatment options.
Purpose of the Study:
- To comprehensively analyze the molecular and biochemical characteristics of PDGFRB, PDGFRA, and KIT in 31 chordoma patients.
- To investigate the activation mechanisms and potential therapeutic targets for chordoma.
Main Methods:
- Immunoprecipitation, Western blot, and immunohistochemistry were used to assess receptor activation status.
- Real-time PCR and cDNA sequencing analyzed receptor expression levels and mutations.
- Reverse transcription-PCR and fluorescence in situ hybridization examined ligand presence and gene status.
Main Results:
- PDGFRB was highly expressed and phosphorylated; PDGFRA and KIT were less expressed but also activated.
- Absence of gain-of-function mutations and presence of cognate ligands suggest an autocrine/paracrine loop drives activation.
- Gene amplification did not appear to play a significant role in receptor activation.
Conclusions:
- The clinical benefit of imatinib in chordoma patients is likely due to the inhibition of PDGFRB, PDGFRA, and KIT.
- Targeting these three receptors offers a potential therapeutic strategy for chordoma.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
01:26Receptor Tyrosine Kinases